95 related articles for article (PubMed ID: 37717650)
21. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
[TBL] [Abstract][Full Text] [Related]
22. The impact of variant and vaccination on SARS-CoV-2 symptomatology; three prospective household cohorts.
Westerhof I; de Hoog M; Ieven M; Lammens C; van Beek J; Rozhnova G; Eggink D; Euser S; Wildenbeest J; Duijts L; van Houten M; Goossens H; Giaquinto C; Bruijning-Verhagen P
Int J Infect Dis; 2023 Mar; 128():140-147. PubMed ID: 36566773
[TBL] [Abstract][Full Text] [Related]
23. Assessment of clinical characteristics and viral load in individuals infected by Delta and Omicron variants of SARS-CoV-2.
Nunes SLP; de França CA; Rocha GD; Oliveira SAS; Freitas MR; da Silva EO; Coutinho KS; Jerônimo AS; de Lima GB; de Lima RE; Bezerra MF; Dezordi FZ; Paiva MHS; Wallau GDL; de Souza CDF; Armstrong ADC; do Carmo RF
Heliyon; 2023 Aug; 9(8):e18994. PubMed ID: 37600420
[TBL] [Abstract][Full Text] [Related]
24. The Dynamics of COVID-19 in Hiroshima Prefecture Compared to Japan and Its Association With Meteorological Factors: A Comparative Analysis.
Hussain MRA; Shaba SSE; Bunthen E; Eity KF; Roshid MM; Kuddus MA
Cureus; 2024 Apr; 16(4):e57708. PubMed ID: 38711698
[TBL] [Abstract][Full Text] [Related]
25. Trend and Co-occurrence Network of COVID-19 Symptoms From Large-Scale Social Media Data: Infoveillance Study.
Wu J; Wang L; Hua Y; Li M; Zhou L; Bates DW; Yang J
J Med Internet Res; 2023 Mar; 25():e45419. PubMed ID: 36812402
[TBL] [Abstract][Full Text] [Related]
26. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
[TBL] [Abstract][Full Text] [Related]
27. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.
Iuliano AD; Brunkard JM; Boehmer TK; Peterson E; Adjei S; Binder AM; Cobb S; Graff P; Hidalgo P; Panaggio MJ; Rainey JJ; Rao P; Soetebier K; Wacaster S; Ai C; Gupta V; Molinari NM; Ritchey MD
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):146-152. PubMed ID: 35085225
[TBL] [Abstract][Full Text] [Related]
28. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
29. A Quick Displacement of the SARS-CoV-2 variant Delta with Omicron: Unprecedented Spike in COVID-19 Cases Associated with Fewer Admissions and Comparable Upper Respiratory Viral Loads.
Fall A; Eldesouki RE; Sachithanandham J; Morris CP; Norton JM; Gaston DC; Forman M; Abdullah O; Gallagher N; Li M; Swanson NJ; Pekosz A; Klein EY; Mostafa HH
medRxiv; 2022 Jan; ():. PubMed ID: 35118480
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study.
Mimura W; Ishiguro C; Maeda M; Murata F; Fukuda H
Int J Infect Dis; 2022 Dec; 125():58-60. PubMed ID: 36220547
[TBL] [Abstract][Full Text] [Related]
31. Maternal and perinatal outcomes of SARS-CoV-2 infection in unvaccinated pregnancies during Delta and Omicron waves.
Birol Ilter P; Prasad S; Mutlu MA; Tekin AB; O'Brien P; von Dadelszen P; Magee LA; Tekin S; Tug N; Kalafat E; Khalil A
Ultrasound Obstet Gynecol; 2022 Jul; 60(1):96-102. PubMed ID: 35441407
[TBL] [Abstract][Full Text] [Related]
32. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
[TBL] [Abstract][Full Text] [Related]
33. Coronavirus disease 2019 transmission and symptoms in young children during the severe acute respiratory syndrome coronavirus 2 Delta variant and Omicron variant outbreaks.
Akaishi T; Ishii T
J Int Med Res; 2022 May; 50(5):3000605221102079. PubMed ID: 35619217
[TBL] [Abstract][Full Text] [Related]
34. Post-COVID Syndrome: The Stranger Ghost of Culprit COVID-19.
Bhandari S; Rankawat G; Joshi S; Tiwaskar M; Lohmror A; Bhandari S
J Assoc Physicians India; 2023 Feb; 71(2):11-12. PubMed ID: 37354471
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study.
Castelli JM; Rearte A; Olszevicki S; Voto C; Del Valle Juarez M; Pesce M; Iovane AN; Paz M; Chaparro ME; Buyayisqui MP; Markiewicz MB; Landoni M; Giovacchini CM; Vizzotti C
BMJ; 2022 Nov; 379():e073070. PubMed ID: 36450402
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Symptoms Associated With SARS-CoV-2 Variants Among Children in Canada.
Sumner MW; Xie J; Zemek R; Winston K; Freire G; Burstein B; Kam A; Emsley J; Gravel J; Porter R; Sabhaney V; Mater A; Salvadori MI; Berthelot S; Beer D; Poonai N; Moffatt A; Wright B; Freedman SB;
JAMA Netw Open; 2023 Mar; 6(3):e232328. PubMed ID: 36892839
[TBL] [Abstract][Full Text] [Related]
37. Awareness of SARS-CoV-2 Omicron Variant Infection Among Adults With Recent COVID-19 Seropositivity.
Joung SY; Ebinger JE; Sun N; Liu Y; Wu M; Tang AB; Prostko JC; Frias EC; Stewart JL; Sobhani K; Cheng S
JAMA Netw Open; 2022 Aug; 5(8):e2227241. PubMed ID: 35976645
[TBL] [Abstract][Full Text] [Related]
38. Clinical characteristics of the Omicron variant - results from a Nationwide Symptoms Survey in the Faroe Islands.
Petersen MS; Í Kongsstovu S; Eliasen EH; Larsen S; Hansen JL; Vest N; Dahl MM; Christiansen DH; Møller LF; Kristiansen MF
Int J Infect Dis; 2022 Sep; 122():636-643. PubMed ID: 35811082
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics of the severe acute respiratory syndrome coronavirus 2 omicron variant compared with the delta variant: a retrospective case-control study of 318 outpatients from a single sight institute in Japan.
Suzuki K; Ichikawa T; Suzuki S; Tanino Y; Kakinoki Y
PeerJ; 2022; 10():e13762. PubMed ID: 35935257
[TBL] [Abstract][Full Text] [Related]
40. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
